106 results on '"Vlachogiannakos, John"'
Search Results
2. Incidence and risk factors of acute kidney injury in cirrhosis: a systematic review and meta-analysis of 5,202,232 outpatients, inpatients, and ICU-admitted patients.
3. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use.
4. Role of Spleen Stiffness Measurement by 2D-Shear Wave Elastography in Ruling Out the Presence of High-Risk Varices in Cirrhotic Patients
5. Evaluation of Plasma Trace Elements in Different Stages of Nonalcoholic Fatty Liver Disease
6. Effect of infliximab on the healing of intestinal anastomosis. An experimental study in rats
7. Sedation during endoscopic procedures: a Hellenic Society of Gastroenterology Position Statement.
8. Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece
9. Is there a role for second-look capsule endoscopy in patients with obscure GI bleeding after a nondiagnostic first test?
10. Serum zonulin levels in patients with liver cirrhosis: Prognostic implications
11. Earlier Eradication of Intra-Anal Warts with Argon Plasma Coagulator Combined with Imiquimod Cream Compared with Argon Plasma Coagulator Alone: A Prospective, Randomized Trial
12. Impact of capsule endoscopy in obscure small-bowel bleeding: defining strict diagnostic criteria for a favorable outcome
13. Acute liver failure as the first manifestation of severe traumatic tricuspid valve insufficiency
14. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic
15. Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: A prospective, randomized, placebo-controlled trial
16. Bowel preparation increases the diagnostic yield of capsule endoscopy: a prospective, randomized, controlled study
17. EFFECT OF OCTREOTIDE AND CORTICOSTEROIDS ON HUMAN SPHINCTER OF ODDI MOTILITY
18. Two different doses and duration schedules of somatostatin -14 in the treatment of patients with bleeding oesophageal varices: a non-randomised controlled study
19. Assessment of dietary habits and the adequacy of dietary intake of patients with cirrhosis-the KIRRHOS study.
20. Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis
21. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: A multicenter randomized controlled trial
22. Successful recanalization of portal vein thrombosis before liver transplantation using transjugular intrahepatic portosystemic shunt
23. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease
24. High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis.
25. Tu1586 – Do Ppis Affect the Incidence of Liver-Related Complications and Overall Survival in Patients with Cirrhosis? the Experience of a Greek Tertiary Hospital
26. Su1090 – The Role of Zonulin in Bacterial Translocation and in the Prognosis of Patients with Liver Cirrhosis
27. Tu1562 - Increased Frequency of Peptic Ulcers Diagnosed During Screening Endoscopy in Asymptomatic Patients with Advanced Chronic Liver Disease
28. Tu1558 - An External Validation of the Baveno VI and Expanded Baveno VI Criteria on Attempting to Transform them into a One Stop Liver Shop
29. Mo1512 - Treatment of Functional Chest Pain: Citalopram, Amitriptylin or no Treatment
30. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
31. Clinical and epidemiological characteristics of hepatitis C virusinfected people who inject drugs: a Greek descriptive analysis.
32. Sa1512 - Predictors of Sustained Virological Response (SVR) in Patients with Advanced Chronic Hepatitis C (CHC) Treated with Current Direct Acting Antiviral(s) (DAA). Heraclis: Hellenic Multicenter Real-Life Cohort Study
33. Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease.
34. Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.
35. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis.
36. Monolobar Caroli's disease complicated by cholangiocarcinoma in a 70-year-old man, previously asymptomatic
37. Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-Blind, Placebo-Controlled Study.
38. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus.
39. Impact of Capsule Endoscopy in Obscure Gastrointestinal Bleeding: Defining Strict Diagnostic Criteria for a Favorable Outcome
40. Letters to the Editor: Two different doses and duration schedules of somatostatin -14 in the treatment of patients with bleeding oesophageal varices: a non-randomised controlled study
41. Should We Routinely Administer Orally a Mucolytic/Antifoam Solution Prior to Upper Gastrointestinal Endoscopy? Results of a Randomised Controlled Study.
42. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
43. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
44. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B
45. Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B.
46. Serum zonulin levels in patients with liver cirrhosis: Prognostic implications.
47. Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis.
48. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
49. Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
50. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.